How to optimize HCV therapy in genotype 1 patients: predictors of response. (Q38071384)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2013

edit

Language	Label	Description	Also known as
English	How to optimize HCV therapy in genotype 1 patients: predictors of response.	scientific article published on February 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

review article

1 reference

stated in

Europe PubMed Central

title

How to optimize HCV therapy in genotype 1 patients: predictors of response (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

author

Antonio Craxì

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

Salvatore Petta

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

author name string

Salvatore Petta

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

retrieved

28 August 2017

publication date

1 February 2013

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

published in

Liver International

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

volume

33 Suppl 1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

page(s)

23-29

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

cites work

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Telaprevir for Retreatment of HCV Infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Factors that predict response of patients with hepatitis C virus infection to boceprevir

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Genomics and HCV infection: progression of fibrosis and treatment response

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FLIV.12053

retrieved

21 January 2018

Identifiers

DOI

10.1111/LIV.12053

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

PubMed publication ID

23286842

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23286842

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23286842%20AND%20SRC:MED&resulttype=core&format=json

retrieved

21 February 2020

ResearchGate publication ID

264483733

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38071384&oldid=2098967912"